HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J's Baby, Beauty Sectors Boost Consumer Health Sales Rebound

This article was originally published in The Rose Sheet

Executive Summary

Johnson’s baby product sales picked up in the third quarter after a rough start as its baby care division sales up 20% in the US to $120m. US consumer health sales grew 6.6% to $1.37bn, also helped by total worldwide beauty sales increasing 6.5% to $1.08bn.

You may also be interested in...



J&J Making Offer For J-Beauty Firm Ci:z Amid Throes Of Consumer Biz Revival

Johnson & Johnson intends to buy out Japan-based Ci:z Holdings for north of $2bn, which would give it full ownership of the firm’s dermocosmetic brand portfolio, including Dr.Ci:Labo, a standout performer for J&J’s beauty and larger consumer business in 2018.

J&J Relaunches Johnson’s Baby Care As Greener, Gentler, With Fewer Ingredients

The overhaul in line with “modern parents’ preferences” could be what’s needed to rouse the sleepy brand and spur Consumer business growth.

J&J Baby Care Launches Crucial To Second-Half Consumer Business Results

Baby care products sales were a drag on J&J's consumer sector, falling at a reported 7.7% to $456m. US sales particularly were off, down reported21.2% to $89m, and international results were off 3.7% to $367m. Worldwide beauty sales were up a reported 3.1% to $1.11bn, but US sales were down 1.8% to $637m.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel